Postecoglou recalls toad pitch invasion before Spurs’ FA Cup trip to Tamworth
Patrik Schick and Bayer Leverkusen’s flying start catches Dortmund cold
Novak Djokovic’s claim he ate ‘poisoned’ food in 2022 Melbourne hotel detention ‘possible but very unlikely’, experts say
Potter’s spell starts with FA Cup exit as Aston Villa battle back to beat West Ham
Male mosquitoes to be genetically engineered to poison females with semen in Australian research
Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease
Federal health authorities on Tuesday gave approval to an experimental new drug that has shown to delay the onset of Alzheimer’s disease in trials.
Donanemab, manufactured by Eli Lilly, is the second medication that has won the blessing of the Food and Drug Administration (FDA) to treat patients showing early symptoms of the disease, most prominently cognitive impairment.
More Stories
Male mosquitoes to be genetically engineered to poison females with semen in Australian research
Bizarre Australian mole even more unusual than first thought, new research reveals
Breakthrough drugs herald ‘new era’ in battle against dementia, experts predict